Acute myeloid leukemia with mutated NPM1
MONDO:0044923An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.
Also known as: AML with mutated NPM1, AML, Mutation of the Nucleophosmin Gene, AML, NPM1 Mutation, AML, NPM1 gene mutation, AML, Nucleophosmin Gene Mutation, NPMc+ AML, acute myeloid leukaemia with cytoplasmic nucleophosmin, acute myeloid leukemia with cytoplasmic nucleophosmin
3105 clinical trials for this condition and its sub-types, 25 tagged with Acute myeloid leukemia with mutated NPM1 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New hope for Hard-to-Treat leukemia: targeted pill combined with chemotherapy enters human trials
Disease control OngoingThis early-stage trial is testing a new oral drug called SNDX-5613 alongside standard intensive chemotherapy in people newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A, NPM1, or NUP98). The study aims to see if the combination is safe and…
Phase 1 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New cell therapy aims to stop blood cancer relapse in tough-to-treat patients
Disease control CancelledThis early-phase study tests a new cell therapy called BSB-2002 in adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to at least two prior treatments. The main goals are to check safety and see if it can prevent the cancer from coming …
Phase 1 • Sponsor: BlueSphere Bio, Inc • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC